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Abstract 
Background: Clostridium difficile (CD), a spore-forming and toxin-producing bacterium, is the main cause for anti-
biotic-associated diarrhea in the elderly. Here we investigated CD colonization in novel in vitro fermentation models 
inoculated with immobilized elderly fecal microbiota and the effects of antibiotic treatments.
Methods: Two continuous intestinal PolyFermS models inoculated with different immobilized elder microbiota 
were used to investigate selected factors of colonization of CD in proximal (PC, model 1) and transverse-distal (TDC, 
model 1 and 2) colon conditions. Colonization of two CD strains of different PCR ribotypes, inoculated as vegetative 
cells (ribotype 001, model 1) or spores (ribotypes 001 and 012, model 2), was tested. Treatments with two antibiotics, 
ceftriaxone (daily 150 mg L−1) known to induce CD infection in vivo or metronidazole (twice daily 333 mg L−1) com-
monly used to treat CD, were investigated in TDC conditions (model 2) for their effects on gut microbiota composi-
tion (qPCR, 16S pyrosequencing) and activity (HPLC), CD spore germination and colonization, and cytotoxin titer (Vero 
cell assay).
Results: CD remained undetected after inoculating vegetative cells in PC reactors of model 1, but was shown to 
colonize TDC reactors of both models, reaching copy numbers of up to log10 8 mL
−1 effluent with stable production 
of toxin correlating with CD cell numbers. Ceftriaxone treatment in TDC reactors showed only small effects on micro-
biota composition and activity and did not promote CD colonization compared to antibiotic-free control reactor. In 
contrast, treatment with metronidazole after colonization of CD induced large modifications in the microbiota and 
decreased CD numbers below the detection limit of the specific qPCR. However, a fast CD recurrence was measured 
only 2 days after cessation of metronidazole treatment.
Conclusions: Using our in vitro fermentation models, we demonstrated that stable CD colonization in TDC reactors 
can be induced by inoculating CD vegetative cells or spores without the application of ceftriaxone. Treatment with 
metronidazole temporarily reduced the counts of CD, in agreement with CD infection recurrence in vivo. Our data 
demonstrate that CD colonized an undisturbed microbiota in vitro, in contrast to in vivo observations, thus suggest-
ing an important contribution of host-related factors in the protection against CD infection.
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Background
Clostridium difficile (CD) was first identified in the 1970s 
as the causative agent of antibiotic-associated pseu-
domembranous colitis and is now the leading cause of 
hospital-acquired diarrhea [1]. CD is a gram-positive 
anaerobic bacterium harboring several virulence factors 
such as the ability to form spores and produce toxins [2]. 
Interestingly, CD is part of the normal gut microbiota 
in 25–80% of infants but usually does not cause disease 
despite the finding that a significant fraction of the CD 
strains are toxin producers [3]. One of the main functions 
of an undisturbed gut microbiota is resistance against 
colonization of pathogens [4]. The disruption of the 
microbiota and thus the colonization resistance is usually 
the first step in the pathogenesis of CD infection (CDI). 
Following ingestion of CD spores, germination into the 
vegetative form is necessary for colonization in the gut, 
with subsequent toxin production leading to clinical 
manifestations [5].
Treatment with broad-spectrum antibiotics, such as 
ampicillin, clindamycin and third-generation cepha-
losporins (ceftriaxone, cefotaxime and ceftazidime) 
are considered to be main risk factors for CDI [6]. The 
elderly population is especially at risk of developing CDI, 
with CD colonization rates of up to 73% in inpatients 
above 65 years [7]. Standard therapy for CDI is antibiotic 
treatment with metronidazole or vancomycin. However, 
efficacy of these antibiotics is limited, with recurrence 
being observed in 20–40% of cases, mainly due to devel-
opment of antibiotic resistances and a loss of gut barrier 
function that allows residual CD to re-colonize the colon 
after the antibiotic treatment is cancelled [1]. Indeed, the 
important role of an undisturbed microbiota that pro-
vides colonization resistance is reflected in the high suc-
cess rate of fecal microbiota transplantation of up to circa 
92% that is used in severe CDI cases [8].
Various animal models have been used to study the 
mechanisms underlying CDI and investigate antibiotic 
treatments. However, the use of animals is limited, pri-
marily owing to ethical and practical reasons and notable 
inter-species differences in susceptibility to CDI. In vitro 
gut fermentation models represent an innovative techno-
logical platform consisting of multiple model designs that 
permit investigations, including survival or mechanistic 
studies on commensal–pathogen interactions and drug 
testing [9, 10]. Different in  vitro intestinal models with 
CDI, from simple batch to multistage continuous sys-
tems, have also been reported [11]. Batch cultures were 
mainly used to study CD interactions with fecal micro-
biota with the aim to test alternative treatments to antibi-
otics [12–15]. A three-stage intestinal model which may 
be more representative for colonic conditions, inoculated 
with pooled fecal microbiota from elderly donors was 
applied in a series of studies with different CD ribotypes 
and antibiotic treatments, as reviewed by Best et  al. 
[11]. With this model CD spores were inoculated while 
the antibiotic clindamycin was used to induce CD spore 
germination [16–18]. However, monitoring of intestinal 
microbiota composition was limited to culture-based 
methods targeting a restricted range of gut bacteria, and 
no metabolic assessment was reported. To date, no study 
has reported in-depth analysis of CD colonization ability 
in in vitro continuous fermentation models using molec-
ular methods and next generation sequencing to describe 
microbiota effects.
We have recently developed a new PolyFermS continu-
ous model platform inoculated with immobilized fecal 
microbiota that mimics different sections of the elderly 
colon [19]. We showed that the models closely reproduce 
the gut microbiota composition, density and activity of 
the fecal donor. Furthermore, the PolyFermS platform 
allows simultaneous testing of several treatments com-
pared to a control in parallel reactors inoculated with the 
same fecal microbiota generated in the upstream inocu-
lum reactor (IR) seeded with fecal beads inoculated with 
single donor microbiota [20, 21]. The aim of the present 
study was to investigate colonization of CD vegetative 
cells and spores (PCR ribotype 001 and 012) in the new 
PolyFermS model of elderly colonic fermentation. Fur-
ther, the effects of two antibiotics, ceftriaxone and met-
ronidazole, were tested on the composition (qPCR, 16S 
pyrosequencing) and activity (HPLC) of the gut microbi-
ota. CD growth and toxin production were analyzed with 
specific qPCR and Vero cell assays, respectively.
Results
Continuous fermentation models mimicking the elderly 
colon
Testing of CD colonization and antibiotic treatments was 
performed in PolyFermS continuous fermentation mod-
els inoculated with fecal beads immobilizing elderly gut 
microbiota, and operated with conditions mimicking the 
elderly proximal (PC) and transverse-distal colon (TDC) 
[19]. Models 1 and 2 were composed of an inoculum 
reactor (IR) seeded with 30% (v/v) fecal beads, operated 
with proximal colon conditions, and used to inoculate 
(10% (v/v)) different second-stage reactors mounted 
in parallel. Mounted in series with IR, model 1 had two 
parallel sets of 2-stage reactors mimicking the proximal 
and distal colon whereas only one set was used to test CD 
colonization in this study. Model 2 was designed with five 
reactors mounted in parallel (one control CR and four 
treatment reactors TR1-4), and mimicking conditions of 
the transverse-distal colon regions (Fig. 1a, b). Investiga-
tion of the model microbiota using qPCR, pyrosequenc-
ing and HPLC revealed high diversity similar to the fecal 
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Fig. 1 Experimental design of the two continuous fermentation models. a Model 1 vegetative CD cells of strain DSM 1296 were added to PC on 
day 1 and growth was observed in PC and TDC during 16 days. b Model 2 CR and TRs were fed with 100% effluent from IR during period A; and 
with fresh fermentation medium during periods B–F. Addition of CD spores (107 cfu) of strain 1296 or 13307 was performed in TRs as indicated. IR, 
inoculum reactor; CR, control reactor; TR, test reactor. CRO I, 75 mg L−1 ceftriaxone addition twice daily; CRO II + III, 150 mg L−1 ceftriaxone addition 
once daily; CD, C. difficile; MTZ, metronidazole; REC, recovery
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donor’s microbiota, stable metabolic activity over long 
time operation periods of up to 76 days, and good repro-
ducibility of control and test reactors inoculated with the 
same microbiota generated in the immobilized cell reac-
tor (IR) within a PolyFermS model [19].
Colonization of CD vegetative cells
In a preliminary test colonization of CD vegetative cells 
of strain DSM 1296, a clinical isolate of PCR ribotype 
001, was evaluated in the continuous fermentation model 
1 seeded with fecal beads of a 72-year old female donor. 
Vegetative cells of strain 1296 were spiked in PC (log10 
9.8 cfu in 250 mL), and CD colonization was monitored 
by qPCR using a specific primer during 16 days continu-
ous fermentation (Table 1). After 6 h the gene copy (GC) 
number of CD was 7.4 and 7.3 log10 GC mL−1 in PC and 
TDC reactors, respectively. In both reactors a wash-out 
was observed until day 3, when CD numbers were below 
the detection limit of the qPCR test (log10 4.4 GC mL−1). 
However, CD was detected again after day 9 of continu-
ous culture in TDC, reaching high copy numbers of log10 
7.8 mL−1 after day 16. Since CD remained under detec-
tion limit in PC, fermentation model 2 was designed to 
target CD colonization in TDC conditions.
Effect of ceftriaxone on gut microbiota composition, 
diversity and metabolites
Treatment with ceftriaxone (150  mg  L−1 per day) was 
investigated in TDC conditions in model 2 inoculated 
with fecal beads containing the microbiota from a 78-year 
old woman (Fig.  1b). During the first period A CR and 
TRs (TDC conditions) were connected to IR and con-
tinuously fed with 100% effluent from IR mimicking PC 
conditions. No significant differences in bacterial group 
concentrations in effluent samples of antibiotic-treated 
reactors and CR were observed using qPCR (period A, 
Table 2; Fig. 2a). We therefore assumed that continuous 
supply of inoculum effluent from IR (100% v/v) may have 
masked the effect of the antibiotic on the gut microbiota. 
Consequently, for the next treatment period with ceftri-
axone (period B) CR and TRs were disconnected from 
IR and were fed with fresh fermentation medium only. A 
significant decrease of 1.5 log10 in Bifidobacterium spp. 
was observed in both TR1 and TR3 upon ceftriaxone 
treatment compared to CR. Small but significant differ-
ences were observed for the copy numbers of Clostridium 
cluster IV (significant for TR3 and TR4) and Roseburia 
spp. (significant for TR3) that were lower in TRs relative 
to CR (period B, Table  2). The microbial composition 
and diversity of effluent samples of TR3 was determined 
with pyrosequencing and compared to CR during the last 
3 days of the second ceftriaxone treatment (period B). A 
similar composition was measured at the genus level in 
TR3 and CR (Additional file 1), with overlapping clusters 
based on UniFrac distances (Fig. 3). The average Shannon 
diversity index measured in effluent samples of the three 
last days of period B in TR3 and CR were similar, with 
3.9 ± 0.2 and 3.8 ± 0.2, respectively.
Metabolite concentration profiles during fermentation 
periods A and B are illustrated for TR1 and compared to 
CR (Fig. 2b). Metabolite profiles in TR3 were similar to 
TR1 (Additional file 2). Mean metabolite concentrations 
measured during the three last days of each period for 
CR, TR1 and TR3 are presented in Table  3. Metabolite 
concentrations were similar in ceftriaxone treated reac-
tors TR1 and TR3 and in CR during both periods A and 
B when reactors were connected and disconnected from 
IR, respectively. However, slight but significantly higher 
acetate concentration in TR3 period B were observed. 
Re-stabilization of the metabolites in CR after disconnec-
tion lasted approximately 5 days (Additional file 3).
Colonization of CD spores and susceptibility to ceftriaxone
The effect of ceftriaxone treatment on spore outgrowth 
and colonization of CD strains 1296 and 13307 was 
investigated in TRs of model 2 mimicking TDC condi-
tions (Fig.  1). In fermentation period A (with CR and 
TRs connected to IR) CD spores (107  cfu) were spiked 
Table 1 Gene copy (GC) number of CD strain 1296 in prox-
imal (PC) and  transverse-distal (TDC) colon reactors 
of model 1
Data are mean log10 16S rRNA GC mL
−1 fermentation effluent from 6 h after 
CD vegetative cells inoculation (log10 9.8 cfu in 250 mL volume PC reactor) and 
during the following 16 days. Samples were analyzed in duplicate. The detection 
limit of qPCR of CD was log10 4.4 GC mL
−1
PC, proximal colon; TDC, transverse-distal colon; CD, C. difficile; ND, not detected
Days post  
CD instillation
Reactors
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in TR1 and TR2 (strain 1296), and in TR3 and TR4 
(strain 13307). Treatment with ceftriaxone (75  mg  L−1, 
twice daily) was performed simultaneously in TR1 and 
TR3 to induce spore germination. Unexpectedly, CD 
growth was not detected in any of the test reactors after 
5 days. In fermentation period B (with CR and TRs dis-
connected from IR) a second inoculation of CD spores 
(107 cfu), similar to period A, was applied on two con-
secutive days. Ceftriaxone treatment (150 mg L−1, once 
daily) was also applied in TR1 and TR3 for 5  days. CD 
strain 13307 growth was detected after 2 and 5 days in 
TR3 with and TR4 without antibiotic, respectively. CD 
strain 1296 was detected after 4  days in TR2 where no 
antibiotic was added (Fig. 4a).
During period C, CD spores (107  cfu) of strain 13307 
were instilled twice in TR1 (with ceftriaxone) where no 
growth of CD strain 1296 was detected during period B 
after 5 days, and in TR2 (without ceftriaxone). No effects 
were measured for the additional spore inoculation in 
TR2, while in TR1 CD growth was not detected after 
5  days, but occurred on day 4 of period D when ceftri-
axone was removed. CD GC numbers of log10 8.8 mL−1 
were measured at the end of period D (Fig. 4b).
Similar high CD numbers of 8.3–8.7 log10 GC  mL−1 
were determined in TR2, TR3 and TR4 15 days after the 
first inoculation of spores corresponding to the end of 
period C (Fig.  4a). Cytotoxin activity in TR2–TR4 was 
first detected shortly after CD cell growth, and ranged 
between 2.9 and 3.9 log10 cytotoxin titer mL−1, with high-
est cytoxin titers measured in TR2.
Effect of metronidazole on gut microbiota composition, 
diversity and metabolites
The effect of metronidazole (333  mg  L−1 added twice 
daily) on gut microbiota composition and metabolites 
in TR1 and TR4 was investigated in period E. The mean 
concentrations of bacterial groups analyzed with qPCR 
and metabolites calculated over the last 3  days of the 
period and compared with CR are presented in Tables 2 
and 3. The relative abundance of selected bacterial 
groups analyzed with qPCR and the metabolite concen-
trations were determined during the entire fermentation 
period, and illustrated for TR4 and CR (Fig.  2c, d). The 
metabolic profile in TR1 was similar to TR4 (Additional 
file 4). Microbial diversity was additionally assessed with 
pyrosequencing during the last 3  days in CR and TR4 
(Figs.  3, 5). Metronidazole considerably affected the 
microbial composition. A decrease in copy numbers of 
Enterobacteriaceae, F. prausnitzii, Clostridium cluster IV 
and Roseburia spp. of up to 3.8 log10 GC mL−1 was meas-
ured in TR1 and TR4 during the last 3 days of metroni-
dazole treatment compared to CR (period E, Table  2). 
In contrast, an increase of Bifidobacterium spp. (2.4 and 
2.3 log10 GC  mL−1 in TR1 and TR4, respectively) was 
measured during metronidazole treatment compared to 
CR. Pyrosequencing of TR4 effluent samples revealed a 
Table 2 Gene copy (GC) number of bacterial groups in TDC reactors of model 2 during antibiotic treatment [A, B and E] 
and recovery [F] periods
Data are mean log10 GC mL
−1 fermentation effluent ± SD of the last 3 days of the treatment periods; samples were analyzed in duplicates
Means with an asterisk differ significantly from the control reactor within the same bacterial group (p < 0.05)















Period A (CRO I)
 CR 11.3 ± 0.2 10.3 ± 0.1 9.8 ± 0.2 7.3 ± 0.3 8.4 ± 0.3 9.0 ± 0.1 9.8 ± 0.2 7.4 ± 0.1
 TR1 11.2 ± 0.2 10.1 ± 0.1 9.7 ± 0.1 7.3 ± 0.2 8.3 ± 0.4 8.9 ± 0.1 9.7 ± 0.2 7.4 ± 0.1
 TR3 11.4 ± 0.07 10.1 ± 0.1 9.8 ± 0.3 7.5 ± 0.1 8.2 ± 0.1 8.9 ± 0.2 9.5 ± 0.5 7.4 ± 0.1
Period B (CRO II)
 CR 11.3 ± 0.4 10.3 ± 0.5 9.6 ± 0.3 8.3 ± 0.3 8.2 ± 0.2 8.9 ± 0.3 9.1 ± 0.2 6.5 ± 0.1
 TR1 11.3 ± 0.04 10.6 ± 0.3 9.7 ± 0.2 8.3 ± 0.1 6.7 ± 0.2* 8.6 ± 0.4 8.8 ± 0.1* 6.0 ± 0.4
 TR3 11.4 ± 0.1 10.5 ± 0.1 9.5 ± 0.1 8.5 ± 0.2 6.7 ± 0.3* 8.6 ± 0.5 8.8 ± 0.1* 6.1 ± 0.2*
Period E (MTZ)
 CR 10.9 ± 0.2 9.6 ± 0.2 10.4 ± 0.2 7.6 ± 0.2 7.1 ± 0.3 9.1 ± 0.1 9.7 ± 0.1 5.8 ± 0.1
 TR1 11.2 ± 0.2 9.5 ± 0.2 9.4 ± 0.5* 7.7 ± 0.3 9.5 ± 0.2* 5.7 ± 0.1* 5.9 ± 0.2* 5.1 ± 0.2*
 TR4 11.1 ± 0.1 9.7 ± 0.2 9.3 ± 0.3* 8.1 ± 0.3 9.4 ± 0.3* 6.7 ± 0.1* 6.7 ± 0.2* 5.0 ± 0.2*
Period F (REC)
 CR 11.3 ± 0.2 10.2 ± 0.1 10.1 ± 0.4 7.2 ± 0.5 7.1 ± 0.2 8.3 ± 0.2 9.7 ± 0.2 6.4 ± 0.1
 TR1 11.7 ± 0.3 10.3 ± 0.1 10.1 ± 0.3 7.4 ± 0.4 7.6 ± 0.3* 8.2 ± 0.3 8.5 ± 0.03* 6.3 ± 0.1
 TR4 11.3 ± 0.1 10.1 ± 0.2 10.3 ± 0.4 7.4 ± 0.1 7.1 ± 0.1 7.2 ± 0.2* 8.6 ± 0.2* 5.5 ± 0.02*
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profoundly altered microbial profile compared to CR. At 
the phylum level Bacteroidetes decreased from average 
values of 61% in CR to 21% in TR4 and Actinobacteria 
increased from less than 1% in CR to 39% in TR4, while 
Firmicutes and Proteobacteria exhibited less pronounced 
changes within 5% (Additional file 5). At the genus level, 
high relative abundance of up to 21% was observed in 
TR4 for Trueperella, Actinomyces and Enterococcus while 
these genera were at low relative abundance of less than 
1% or undetected in CR (Fig.  5). The mean Shannon 
diversity index measured during the last 3  days of met-
ronidazole treatment was lower in TR4 (3.8 ± 0.03) com-
pared to CR (4.3 ± 0.1; Fig. 4). In addition, PCoA analysis 
showed a clear separation between samples from TR4 
and CR during metronidazole period (Fig. 5).
Similarly, metronidazole also largely impacted gut 
microbiota metabolic activity, with a 50% decrease of ace-
tate concentrations in TR1 and TR4 relative to CR, com-
plete inhibition of butyrate production, and significant 
accumulation of formate (Table  3; Fig.  2d). Propionate 
concentrations decreased from 25 mM to approximately 
4  mM in TR4 during the first 4  days of metronidazole 































































































Fig. 2 Effect of antibiotic treatment on gut microbial groups and metabolites. a Relative abundance of selected microbial groups tested with qPCR 
in CRO treated reactor TR1 relative to CR during period A and B. b Daily mean metabolites concentrations in TR1 and CR during period A and B 
assessed with HPLC. c Relative abundance of selected microbial groups tested with qPCR in MTZ treated reactor TR4 relative to CR during period E 
and F. d Daily mean metabolites concentrations in CR and MTZ treated reactor TR4 during period E and F. CRO ceftriaxone, MTZ metronidazole, REC 
recovery
Fig. 3 PCoA analysis during period B, E and F based on weighted 
UniFrac distance matrix. The three last days of period B (circles), period 
E (squares) and period F (pentagons) are presented for TR3 (period B) 
and TR4 (period E and F) and compared to the same CR period
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reach stable concentrations of 37.0 ± 1.3 mM during the 
last 4 days.
Growth and toxin production of CD during metronidazole 
treatment
During a 10-day treatment of metronidazole (period E) 
in TR1 and TR4 initially colonized with high CD num-
bers (log10 8.8 and 8.5 GC  mL−1, respectively), a rapid 
decrease of CD gene copy number was observed after 
only 1 day, reaching the detection limit of the qPCR test 
after 3 and 6 days in TR1 and TR4, respectively (Fig. 4b). 
The toxin production steadily decreased from 2.8 and 3.6 
log10 cytotoxin titer mL−1 to non-detectable levels fol-
lowing 1 and 2 days of metronidazole treatment in TR1 
and TR4, respectively. Unexpectedly CD was detected 
again at a concentration of log10 6.3 GC mL−1 in TR4 on 
day 9 of antibiotic treatment during period E.
Recovery of gut microbiota and CD after metronidazole 
treatment
The microbiota composition and metabolic activity of 
TR1 and TR4 was monitored over 10 days during period 
F after cessation of metronidazole treatment of period 
E. All bacterial populations analyzed with qPCR showed 
a recovery trend towards CR composition (Fig.  2c; 
Table 2). However, the populations of F. prausnitzii and 
Clostridium cluster IV were significantly lower in TRs 
compared to CR, while Bifidobacterium spp. remained 
higher in TR1 relative to CR at the end of period F, sug-
gesting that the microbiota recovery was incomplete after 
10  days (Table  2). Pyrosequencing data at the phylum 
level showed similar relative abundance for Bacteroidetes 
in TR4 (57%) compared to CR (64%), but Actinobacteria 
levels remained higher in TR4 than in CR (10% versus 
below 1%, Additional file 5). Most genera that increased 
during metronidazole treatment decreased or became 
undetectable during the last 3  days of the recovery 
period (Fig. 5). The Shannon diversity index determined 
at the end of the recovery period was similar in TR4 
(4.5 ± 0.07) compared to CR (4.2 ± 0.2) (Fig. 5). In addi-
tion, PCoA analysis revealed that microbial composition 
of the last 3 days of the recovery period in TR4 clustered 
close to samples from CR of the same treatment period 
(Fig. 3).
Metabolite concentrations in TR1 and TR4 measured 
during the last 3 days of period F were not significantly 
different from that in CR (Table  3; Fig.  2d; Additional 
file 4: Figure S4).
The CD growth and toxin production after cessation 
of metronidazole treatment was monitored for 10  days 
(period F, Fig.  4b). After only 2  days, CD was tested at 
high numbers of approximately log10 9 GC mL−1 in both 
TR1 and TR4 and toxin production was detected. The 
toxin titer in TR1 increased until day 5 to reach 5 log10 
Table 3 Metabolites concentration (mM) and ratios (%) measured by HPLC in model 2 during antibiotic treatment [A, B 
and E] and recovery [F] periods
Data are mean ± SD of the three last days of treatment periods; samples were analyzed in duplicates
Means with an asterisk (*) differ significantly from the control reactor within the same metabolite (p < 0.05)
CR control reactor, TR test reactor, SCFA short-chain fatty acids, CRO ceftriaxone, MTZ metronidazole, REC recovery, ND not detected
Acetate Propionate Butyrate Formate Total metabolites SCFA Ratios (%)
Acetate Propionate Butyrate
Period A (CRO I)
 CR 75.7 ± 4.8 33.4 ± 2.5 38.4 ± 2.2 ND 147.5 ± 5.8 51.3 22.6 26.0
 TR1 75.0 ± 3.0 36.7 ± 4.0 37.4 ± 0.9 ND 148.4 ± 6.4 20.5 24.7 24.7
 TR3 76.5 ± 4.1 33.5 ± 2.0 35.8 ± 1.3 ND 145.8 ± 4.7 52.5 23.0 24.6
Period B (CRO II)
 CR 91.2 ± 0.9 43.6 ± 2.2 18.4 ± 4.6 ND 153.2 ± 5.2 59.5 28.5 12.0
 TR1 93.5 ± 7.4 47.2 ± 4.3 19.5 ± 2.6 ND 160.2 ± 8.9 58.4 29.5 12.2
 TR3 97.0 ± 5.1* 45.6 ± 4.3 19.6 ± 2.1 ND 162.2 ± 7.0 97 45.6 19.6
Period E (MTZ)
 CR 99.2 ± 2.4 37.0 ± 1.2 13.3 ± 0.5 ND 149.5 ± 2.7 66.4 24.7 8.9
 TR1 44.1 ± 0.7* 35.9 ± 1.8 ND 10.6 ± 1.0 90.6 ± 2.2* 55.1 44.9 0
 TR4 45.6 ± 2.5* 37.0 ± 1.3 ND 11.3 ± 1.6 93.9 ± 3.2* 55.2 44.8 0
Period F (REC)
 CR 92.6 ± 10.9 39.9 ± 6.2 13.4 ± 0.2 ND 145.9 ± 12.5 63.5 27.3 9.2
 TR1 83.7 ± 0.4 43.8 ± 2.4 13.4 ± 0.7 ND 140.9 ± 2.5 59.4 31.1 9.5
 TR4 88.4 ± 8.6 44.8 ± 9.8 13.5 ± 1.6 ND 146.7 ± 13.1 60.3 30.5 9.2
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cytotoxin titer mL−1, and steadily decreased thereafter to 
3.7 log10 cytotoxin titer mL−1 after 10  days. In contrast 
toxin production in TR4 remained constant from day 2 to 
10 (mean value of 3.34 ± 0.09).
Discussion
In vitro intestinal fermentation models are useful tools 
to investigate colonization of enteropathogens, such as 
Salmonella, and interactions with the human gut micro-
biota, independent of the effects of the host [22–24]. 
The human colon can be approximated to a continuous 
fermenter, divided in regions (ascending, transverse and 
descending colonic) that are different in metabolic activ-
ity and microbial composition. A major advancement of 
in  vitro gut fermentation models was the development 
of multistage continuous fermentation models which 
enable the simulation of horizontal colon processes [25]. 
Investigation of CD colonization in intestinal models has 
been primarily performed with three-stage colonic mod-
els, inoculated with a liquid fecal suspension from pooled 
donors, using cultivation methods for microbiota analy-
sis [16, 18].
In a recent study we investigated novel in  vitro con-
tinuous colonic fermentation models inoculated with 
immobilized fecal microbiota from single elderly donors 
and characterized in detail microbiota composition, 
diversity and activity [19]. Immobilization of fresh gut 
microbiota reproduced both the planktonic (free-cell) 
and sessile (biofilm-associated) states of bacterial popu-
lations in the colon and yielded self-contained continu-
ous fermentation system of high cell density, diversity 
and population stability, similar to what is observed in 
the human GI tract [9]. In this study, we used two fer-
mentation models to investigate the colonization of CD 
vegetative cells or spores, and the response of the micro-
biota to antibiotics known to induce or used to treat 
CDI.
It is suggested that the small intestine is the site of CD 
spores germination into the metabolically active veg-
etative cells [26, 27], which then proliferate in the large 
Fig. 4 CD gene copy (GC) numbers and cytotoxin titers in TRs of model 2. a Period B and C in TR2-4. CD GC numbers and toxin titers are shown 
starting from first detection of CD growth in TR3 on day 7. TR1 was treated with CRO during period B and C but no CD growth was detected in this 
reactor during these periods. b Period D-F in TR1 and TR4. CD colonization was observed during period D. On day 21 metronidazole treatment [E] 
was performed in TR1 and TR4 for 10 days and followed by a recovery period [F] of 10 days. CD GC numbers and cytotoxin titer were determined by 
qPCR and Vero cell assays, respectively. (—) CD detection limit of 4.4 GC mL−1. CRO, ceftriaxone; CD, Clostridium difficile
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intestine and cause symptoms typical for CDI [5, 28]. 
Using PolyFermS models, we showed that CD vegeta-
tive cells or spores only colonize in TDC reactors after a 
time period of 7–10 days. Our data are in agreement with 
previous studies that reported an absence of CD coloni-
zation added as spores in the proximal colon section of 
a three stage colonic fermentation model [29, 30], which 
may be explained by pH inhibition effect [31].
The CD concentration determined in TDC reactors of 
our models (from 6.0 to 8.9 GC mL−1) is within the range 
of in  vivo qPCR data for feces of antibiotic-associated 
diarrhea patients (aged 3–89 years; from 5.6 to 11.2 cell 
equivalents log10 g−1 [32]). Growth of CD in gut models 
upon inoculation of vegetative cells was only reported 
for batch fermentations, yielding cell counts up to 8 log10 
cfu  mL−1 after 24  h [12, 13]. Although we used a high 
inoculum of vegetative cells (log10 9.8  cfu) in model 1, 
CD cells were washed-out and remained undetected for a 





3 last days of period E (MTZ) 3 last days of period F (REC) 




















































Fig. 5 Effect of metronidazole on microbial composition and diversity measured by 454-pyrosequencing. The microbiota profile in reactor effluents 
of CR and TR4 during the last 3 days of period E and F was analyzed by 454-pyrosequencing of the V5–V6 hypervariable regions of the 16S rRNA 
gene. a Relative abundance at genus level. Values <1% are summarized in the group “others”. b Diversity measured by the Shannon diversity index. 
A higher Shannon diversity index reflects a more diverse community (in abundance and evenness). MTZ metronidazole, REC recovery, uc unclassi-
fied
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The PolyFermS design of model 2 was therefore 
selected to mimic TDC conditions for CD colonization. 
We investigated the colonization of two PCR ribotypes 
of CD spores and the effects of two antibiotics, ceftriax-
one and metronidazole, that are known to respectively 
promote and treat infection. CD remained undetected 
in all TRs for 5 days after which a repeated inoculation 
of spores was performed. This result suggests that either 
the spores were washed out of the system, or that they 
were able to grow, but remained below the detection 
limit of the qPCR method (4.4 GC  mL−1). A quiescent 
state of CD spores for a period of at least 7 days was pre-
viously reported in a three-stage model, and was tenta-
tively explained by the absence of antibiotic treatment 
[29, 30]. Our data demonstrate that application of anti-
biotic may not be required for CD spore germination and 
colonization of an in  vitro continuous colonic fermen-
tation model mimicking TDC conditions of an elderly 
microbiota. This is in contrast to in vivo data in humans 
and animal models suggesting that CD infection is pro-
moted by a disturbed microbiota mainly due to antibiotic 
treatment [6, 33]. This discrepancy between in vitro and 
in vivo CD colonization may be a consequence of host-
specific mechanisms, including the epithelial cell layer 
and immune responses, both of which are lacking in 
in  vitro models. Lawley et  al. [34] showed that CD can 
asymptomatically colonize mice in the absence of antibi-
otic treatment while antibiotics were necessary for CD to 
proliferate and sporulate. The study suggested that toll-
like receptor signaling may protect against virulent CD 
overgrowth.
Ceftriaxone is a broad-spectrum antibiotic that is asso-
ciated with a high risk of developing diarrhea due to CD 
colonization [35, 36]. Pletz et al. [37] reported that in the 
fecal microbiota of ten healthy adults, ceftriaxone treat-
ment (2 g administered once daily for 7 days) induced a 
marked decrease in lactobacilli, bifidobacteria, clostridia 
and Bacteroides, with an attendant increase in ente-
rococci. In the present study, we observed only minor 
effects of ceftriaxone on the gut microbiota when added 
at 150 mg L−1 to mimic ceftriaxone levels found in feces 
of volunteers from the study mentioned above [37] on the 
4th day of the treatment. Bifidobacterium spp. was most 
affected, but diversity and metabolic activity was not 
changed compared to the control reactor. The detrimen-
tal effect of ceftriaxone on Bifidobacterium spp. was also 
observed in the human gut model of Baines [29] when 
the same antibiotic concentration was used to induce CD 
spore germination. In contrast to our study, Baines only 
used plating for gut microbiota enumeration (total facul-
tative anaerobes, total anaerobes (facultative + obligate), 
lactose-fermenting Enterobacteriaceae, enterococci, 
lactobacilli, bifidobacteria, total Clostridium spp. and 
Bacteroides fragilis group), and did not test diversity and 
metabolic effects.
Metronidazole is used in the treatment of anaerobic 
infections [38], including cases of mild to moderate CDI 
[39]. We measured an extreme shift of the gut microbiota 
composition during metronidazole treatment, with a very 
large increase of Actinobacteria at the expense of Bacte-
roidetes and sharp inhibition of butyrate production. A 
detrimental effect of metronidazole on Bacteroidetes 
was also observed in a previous single-stage human dis-
tal colon model which was used to investigate the activity 
of a bacteriocin versus antibiotics against CD, however, 
metronidazole mainly promoted growth of bacteria 
belonging to the phylum Proteobacteria [13]. In previous 
in vitro studies which used concentrations varying greatly 
between 9.3 mg L−1 every 8 h [17] to 330 mg L−1 per day 
[14] no effect on CD counts and toxin production was 
observed with the low antibiotic level [17]. However, CD 
eradication was reported for the higher concentration in 
a batch fermentation which contained a total anaerobes 
concentration of approximately log10 10.3 cfu mL−1, esti-
mated with plate counts [14]. In our model we chose to 
apply a higher antibiotic concentration (333  mg  L−1, 
twice daily) to account for the high total cell numbers 
tested in TDC (in the range of log10 11.1–11.2 GC mL−1 
[19]). Furthermore, we considered that the concentration 
of metronidazole entering the colon is higher than that 
tested in feces since the gut bacteria metabolize the drug 
[40]. With our conditions, we observed a strong reduc-
tion of CD numbers while toxin production decreased 
below the detection limits.
An important issue to consider with treatment of CDI 
is the high recurrence rate after antibiotic treatment, 
typically around 27% after metronidazole treatment [41]. 
Our data consistently demonstrate that a fast recur-
rence of CD occurred only 2 days after cessation of the 
metronidazole treatment, also supporting the applied 
metronidazole dosage. Gut bacterial groups that were 
mainly affected by metronidazole (Clostridium cluster 
IV, F. prausnitzii and Roseburia spp.) showed only partial 
recovery to control levels after 10  days. To our knowl-
edge, this is the first report CD recovery after metronida-
zole treatment in a gut fermentation model.
Conclusions
In conclusion, our study provides evidence to support 
the use of continuous intestinal models for the in  vitro 
investigation of CD colonization dynamics and antibi-
otic treatments on elderly gut microbiota independent of 
host factors. We demonstrated colonization of vegetative 
cells and spores of CD in the gut microbiota under condi-
tions of the transverse-distal colon without requirement 
of an antibiotic treatment. Treatment with metronidazole 
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induced sharp deleterious effects on the gut microbiota 
composition and activity at the tested dosage. However, 
even when applied at high dosage, metronidazole only 
induced a temporary inhibition of CD followed by a rapid 
recurrence after cessation of treatment. Immobiliza-
tion of fecal microbiota in gel beads allowed the inves-
tigation of a high bacterial cell density similar to in vivo 
gut microbiota. The PolyFermS models proved to be 
well-suited for direct comparison of treatment effect to 
control conditions in reactors inoculated with the same 
microbiota and mimicking TDC conditions. However, 
our data suggest that strong host effects are involved with 
CD protection in the gut as suggested by colonization 
occurring in the absence of antibiotics. Consequently, 
in  vitro models lacking host factors may only provide 
partial understanding of the CD colonization mecha-
nisms involved with CDI. Nevertheless, in vitro modeling 
is an important component, especially when combined 
with in vivo investigation of multi-scale strategy for gut 
microbiota investigations and for testing new antimicro-
bial treatments for their activity against CD [10].
Methods
Clostridium difficile strains
Clostridium difficile DSM 1296 (PCR ribotype 001) and 
C. difficile NCTC 13307 (PCR ribotype 012) were pur-
chased from the Deutsche Sammlung von Mikroorganis-
men und Zellkulturen (DSMZ, Braunschweig, Germany) 
and the National Collection of Type Cultures (NCTC, 
Salisbury, UK), respectively. Vegetative cells of CD DSM 
1296 and NCTC 13307 were cultured from glycerol 
stocks (33%, −80  °C) and routinely grown in BHI sup-
plemented with 0.05% (w/v) l-cysteine (BHIS) in anaero-
bic Hungate tubes. Vegetative CD cells for inoculation of 
reactors were grown in serum flasks containing fermen-
tation medium at 37 °C for 15 h. The medium composi-
tion was based on that described by MacFarlane et  al. 
[25] for simulation of adult ileal chyme, and prepared 
according to Fehlbaum et  al. [19]. Anaerobic conditions 
in serum flasks were achieved by flushing the headspace 
with N2 and CO2 at 3:1 ratio. Spores of CD DSM 1296 
and NCTC 13307 were prepared according to Sorg and 
Dineen [42]. Briefly, several large petri dishes were spread 
with 150 µL of an overnight culture of CD and incubated 
in an anaerobic chamber at 37  °C for 10  days. Growth 
on the agar was collected by flooding the agar with ster-
ile ice-cold water. The suspension of vegetative cells and 
spores was kept at 4 °C overnight in order to enhance the 
release of spores from mother cells. The suspension was 
subsequently centrifuged (14,000g, 1 min) and the pellet 
was washed several times with ice-cold water. Histodenz 
(Sigma-Aldrich) was used to separate the free spores 
from vegetative bacteria and cell debris. The spore pellet 
was washed several times with ice-cold water and finally 
resuspended in 200 µL sterile water. For spore enumera-
tion a sample was plated on BHI agar containing 0.1% 
taurocholate (Sigma) and incubated for 48 h in an anaer-
obic chamber at 37 °C. Spore suspensions were adjusted 
to a concentration of 107  cfu  mL−1 using sterile water, 
and kept at 4 °C until further use.
Antibiotics
Rocephin® (ceftriaxone sodium,  >90% purity, Roche, 
Pharma AG, Reinach, Switzerland) was diluted in sterile 
ultra-pure water (1 g in 10 mL) and 340 µL of the solu-
tion was added once a day, or in two separate doses, to 
the reactors corresponding to a total added amount of 
150 mg L−1. This concentration was adapted from Baines 
et al. [29] and is based on fecal ceftriaxone levels found 
in feces of volunteers with a mean concentration of 
152 mg kg−1 on day four of treatment [37].
Crystalline metronidazole (Sigma-Aldrich, Buchs, 
Switzerland) was added twice daily directly to the reac-
tors to achieve a final concentration of 333 mg L−1 with 
each addition. The treatment recommendations for met-
ronidazole during CDI range between 500 and 750  mg 
three times per day [6, 43] and it was suggested that 
6–15% of the antibiotic metabolites are extracted in feces 
[44]. We chose to apply a metronidazole concentration 
higher than tested in feces in vivo to account for absorp-
tion and possible degradation of the antibiotic during 
colonic transit (see discussion section).
Fermentation medium
The fermentation medium was based on the composi-
tion described by MacFarlane et  al. [25] for simulation 
of adult ileal chyme. Ingredients and preparation were 
described previously [19].
Fecal inoculum and fermentation setup
The experimental setup of the two continuous in  vitro 
fermentation models (PolyFermS models) is schemati-
cally illustrated in Fig.  1, and a detailed description of 
the experimental procedure was previously reported 
by Fehlbaum et al. [19]. Briefly, fresh fecal samples were 
obtained from two healthy women aged 72 (model 1) and 
78 (model 2), who did not receive antibiotic treatment for 
at least three months prior to sample collection and who 
did not consume probiotics on a regular basis. The fecal 
microbiota was processed and immobilized in gellan-
xanthan beads as described previously [19].
The two models were composed of a first inoculum 
reactor (IR) seeded with 30% (v/v) polysaccharide fecal 
beads, operated with conditions selected for the elder 
proximal colon (PC, mean retention time of 9 h, pH 5.7). 
In the preliminary setup (model 1) the IR was used to 
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continuously inoculate a reactor (10% v/v IR effluent and 
90% fresh medium) operated with PC conditions (reten-
tion time of 9 h, pH 5.7) that was connected in series to a 
second reactor mimicking transverse-distal colon condi-
tions (TDC, retention time of 18 h, pH 6.8). For model 2 
IR mimicking PC conditions was used to feed (100%) five 
reactors mounted in parallel [one control reactor (CR) 
and four test reactors (TR1-4)], and operated with TDC 
conditions (pH 6.8). During periods B to F, CR and TRs 
were disconnected from IR and were fed with fresh fer-
mentation medium only to avoid masking of the effect of 
the antibiotic on the gut microbiota resulting from con-
tinuous supply of 100% effluent from IR (see “Results” 
section). The retention time of CR and TRs was set to 
25 h, which is also in the range of in vivo measured reten-
tion times for elderly and to account for the overall fer-
mentation taking place in one reactor compared to two in 
model 1 [19].
Experimental design
Establishment and detailed characterization of the colo-
nization and stability of the two continuous colonic fer-
mentation models have previously been described [19].
Model 1 was used to test colonization of vegetative 
cells CD 1296 in PC and TDC conditions. CD cells (log10 
9.8 cfu) were spiked into PC (250 mL fermentation vol-
ume) after 18  days of model stabilization, indicated as 
day 1 (Fig.  1). Effluents of PC and TDC reactors were 
analyzed after 6 h and daily over a total period of 16 days.
Model 2 was used to test the germination of spores 
and colonization of vegetative cells of two CD ribotypes, 
with and without simultaneous treatment with antibi-
otics (ceftriaxone or metronidazole). Treatments were 
applied in TR1-4 operated at TDC conditions during 
six consecutive periods over a total fermentation time 
of 40  days (Fig.  1). CR served as control reactor during 
the entire experiment, with no treatment applied. During 
period A, CD spores (107 cfu) were added once in TR1 
and TR2 (strain 1296) and TR3 and TR4 (strain 13307) 
after 14 days of model stabilization (indicated as day 1). 
Rocephin® was supplied twice daily for 5  days in TR1 
and TR3 at a concentration of 75  mg  L−1 per injection 
in the fermentation volume (Period A). Since no effect 
of antibiotic was observed on microbiota composition 
and activity in TRs, we assumed that continuous feeding 
of effluent with microbiota grown at high concentration 
in IR masked the possible antibiotic effects. Therefore, 
for the subsequent tests (Period B–F), we chose to dis-
connect CR and TRs, all colonized by stable and similar 
microbiota from IR, and fed them 100% fresh fermen-
tation medium. During period B, CD spores (107 cfu, 
strain 1296 in TR1 and TR2, and strain 13307 in TR3 
and TR4) were inoculated on two consecutive days (days 
6 and 7) and ceftriaxone was added once daily for 5 days 
(150 mg L−1) to TR1 and TR3. During period C spores of 
strain 13307 were added to TR1 because no CD coloni-
zation was detected after application of spores of strain 
1296 during period B. CD was allowed to colonize reac-
tors TR1 and TR4 during another 5 days (period D) while 
TR2 and TR3 were used to test other treatments (data 
not shown). During period E, addition of metronidazole 
(333 mg L−1 twice daily) was tested in TR1 and TR4 dur-
ing 10 days, followed by 10 days recovery (period F) with-
out antibiotic addition.
qPCR analysis
Genomic DNA was extracted from fermentation efflu-
ent samples (2  mL) using the FastDNA® SPIN Kit for 
Soil (MP Biomedicals, Illkirch, France) and a final elution 
volume of 100 µL. Total bacteria and specific bacterial 
groups prevalent in the gut were enumerated using pre-
viously described primers [19]. CD was quantified using 
primers (forward, 5′-TTG AGC GAT TTA CTT CGG 
TAA AGA-3′ and reverse, 5′-CCA TCC TGT ACT GGC 
TCA CCT-3′) and conditions described previously [45]. 
One µL of 10- or 100-fold diluted DNA was amplified in 
a total volume of 25 µL as described in Zihler et al. [23] 
using 2× SYBR Green PCR Master Mix (Applied Biosys-
tems, Zug, Switzerland). Each reaction was run in dupli-
cate on an ABI PRISM 7500-PCR sequence detection 
system (Applied Biosystems). For quantification, stand-
ard curves were produced by amplification of the DNA of 
the reference strain of the respective target group.
HPLC analysis
Short chain fatty acids (SCFA; acetate, propionate, 
butyrate and valerate), lactate, formate and branched-
chain fatty acids (BCFA; isobutyrate and isovalerate) 
in fermentation effluent samples from all reactors were 
determined daily by HPLC analysis in duplicate (Thermo 
Fisher Scientific Inc. Accela, Wohlen, Switzerland) [20]. 
Effluent supernatants (500 µL) were twofold diluted with 
sterile ultra-pure water and filtered directly into vials 
through a 0.45  µm nylon HPLC filter (Infochroma AG, 
Zug, Switzerland). The analysis was run at a flow rate of 
0.4 mL min−1 using an Aminex HPX-87H column (Bio-
Rad Laboratories AG, Reinach, Switzerland) and 10 mM 
H2SO4 as eluent.
Microbiota profiling by 454 pyrosequencing
454-pyrosequencing analysis of total genomic DNA was 
carried out at DNAVision (Gosselies, Belgium). The V5–
V6 hypervariable 16S rRNA region was amplified using 
specific primers 784F (5′-AGGATTAGATACCCTK-
GTA-3′) and 1061R (5′-CRRCACGAGCTGACGAC-3′) 
[46]. The forward primer contained the sequence of the 
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Titanium A adaptor and a unique barcode sequence. 
Pyrosequencing was carried out using primer A on a 454 
Life Sciences Genome Sequencer FLX instrument (Roche 
Applied Science, Vilvoorde, Belgium) following Tita-
nium chemistry. The obtained data was analyzed using 
the open source software package Quantitative Insights 
Into Microbial Ecology (QIIME), v1.7 [47]. Briefly, raw 
sequencing reads were filtered based on selected qual-
ity criteria such as: (1) no mismatch with the primer 
sequences and barcode tags; (2) no ambiguous bases 
(Ns); (3) read-lengths not shorter than 200 base pairs (bp) 
or longer than 1000 bp; (4) the average quality score in a 
sliding window of 50 bp not to fall below 25; (5) exclud-
ing homopolymer runs higher than 6 nt. Sequences 
that passed quality filtering were clustered into OTUs 
at 97% identity level using usearch [48]. Representa-
tive sequences (the most abundant) for each OTU were 
aligned using PyNAST and taxonomically assigned using 
Greengenes v_13_08 database. These phylogenies were 
combined with absence/presence or abundance informa-
tion for each OTU to calculate unweighted or weighted 
UniFrac distances, respectively using rarefaction of 7000 
sequences per samples. Principal coordinates analysis 
(PCoA) was applied to the distance matrices for visuali-
zation. Alpha diversity (diversity within sample) was cal-
culated using Shannon (evenness) indexes.
Vero cell analysis
CD toxin production in reactor effluents of model 2 
was estimated using Vero cell cytotoxicity assays as 
previously described [49, 50]. Briefly, 500 µL reactor 
effluent samples were centrifuged (10,000g, 10  min) 
and the supernatant was filtered through a 0.45  µm 
membrane filter (Infochroma AG, Zug, Switzerland) 
and subsequently serially diluted in peptone buffered 
saline (PBS) to 10−7. Twenty µL thereof was then mixed 
with 30  µL of cell media Dulbecco’s Modified Eagle’s 
medium (DMEM, Life Technologies) and added in 
duplicate to Vero cell culture monolayers prepared in 
96-well microtiter plates. The cell culture toxin assay 
trays were incubated at 37  °C in 5% CO2 atmosphere 
and read after 48  h under an inverted microscope. A 
positive cytotoxin activity was indicated by cell round-
ing, with the end-point titer defined as the last dilution 
at which 50% rounded cells were measured. The action 
of CD cytotoxin in the samples was confirmed by neu-
tralization with CD antitoxin (Alere Health BV, Tilburg, 
NL, USA).
Statistical analysis
Statistical analysis of HPLC and qPCR data was per-
formed using JMP 8.0 (SAS Institute Inc., Cary, NC, USA). 
HPLC and qPCR data are expressed as mean ± SD of the 
last 3  days of each treatment period. qPCR data were 
log10-transformed. qPCR and HPLC data among reactors 
were compared using the nonparametric Kruskal–Wallis 
test. p Values <0.05 were considered significant.
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